Biopharma major Biocon is planning to set up a dedicated greenfield facility to manufacture tablet formulations. The Bangalore-based company currently outsources this activity. Biocon is in the tablet formulation market in a small way now across the nephrology, diabetology, cardiology and oncology verticals. This segment accounts for about 10% of Biocons revenues, which it hopes to more than double to 25% in the next three to four years with its own manufacturing facility. Biocon manufactures its own injectable formulations across all bio-pharma verticals that it operates in. TOI had reported in April that Biocon was looking at manufacturing tablet formulations at its upcoming facility in Visakhapatnam. Speaking to TOI this week, Kiran Mazumdar Shaw, CMD of Biocon, said, "We are looking at manufacturing our own tablet formulations, but it definitely won't happen at the new facility in Andhra Pradesh. We are planning to set up a greenfield facility for this purpose which will be finalized only in the next fiscal.' Analysts say this move will widen firm's base in branded formulations market. Mazumdar said the facility would require an investment of a few hundred crore. Testing and development of tablet formulations is happening at firm's formulation development centre in the Biocon Park.